Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study
1 Département d’Infectiologie, CHU Dijon, Dijon, France
2 Université de Bourgogne, Dijon, France
3 Laboratoire de Bactériologie, CHU Dijon, France
4 Service d’Hépato-Gastro-Entérologie, CHU Besançon, France
5 Service de Maladies Infectieuses et Tropicales, CHU Strasbourg, Strasbourg, France
6 Laboratoire de Bactériologie, CHU Besançon, France
7 Laboratoire de Bactériologie, CHU Nancy, France
8 Laboratoire de Bactériologie, CHU Strasbourg, France
9 Service de Maladies Infectieuses et Tropicales, CHU Besançon, France
10 Service de Maladies Infectieuses et Tropicales, CHU Nancy, France
11 Service d’Hépato-Gastro-Entérologie, CHU Dijon, France
BMC Infectious Diseases 2014, 14:287 doi:10.1186/1471-2334-14-287Published: 23 May 2014
Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis (SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed, whether these recommendations are still appropriate must be confirmed.
An observational study that exhaustively collected the clinical and biological data associated with positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011.
Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients (median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 as confirmed bacterascites. The predominant flora was Gram-positive cocci, whatever the situation (SBP, bacterascites, nosocomial/health-care related or not). Enteroccocci (27.7% E. faecium) were isolated in 24% of the episodes, and in 48% from patients receiving quinolone prophylaxis. E. coli were susceptible to amoxicillin-clavulanate and to third-generation cephalosporins in 62.5% and 89.5% of cases, respectively. No single antibiotic allowed antimicrobial coverage of more than 60%. Only combinations such as amoxicillin + third-generation cephalosporin or cotrimoxazole allowed coverage close to 75-80% in non-nosocomial episodes. Combinations based on broader spectrum antibiotics should be considered for empirical therapy of nosocomial infections.
Our study confirmed the changing spectrum of pathogens in SBP and bacterascites, and the need for more complex antibiotic strategies than those previously recommended. Our findings also underline the need for new clinical trials conducted in the current epidemiological context.